Therapeutic Impact of Fluvastatin and Metformin Against Hepatocellular Carcinoma via Cell Viability Assay

Abstract

Hepatocellular carcinoma (HCC) is the most detrimental and intrusive state of liver cancer. The incidence of HCC resumed advancing rapidly, ranking as the sixth most common cancer and the fourth ultimate cause of death. Objective: To evaluate the utility of metformin and fluvastatin, alone or in combination, as potential anticancer therapeutics using human liver cell lines (HepG2). Methods: Four groups were allocated: The control)Group1) consists of HepG2 cells treated with 0.1% dimethyl sulfoxide with an average absorption at 570 nm of 0.651; the fluvastatin (Group 2)in (6.5, 12.5, 25, 50, and 100 μM) concentrations; the metformin (Group 3) in (6.5, 12.5, 25, 50, and 100 mM); and the (Group 4) of 10 mM metformin with fluvastatin in (10, 15, 20, and 40 μM) of HepG2 cell. Results: The results revealed a synergistic effect between metformin and fluvastatin, where the combination is more effective in achieving an IC50 of about 25. These are more potent at reducing cell viability by about 44.62%. Also, combining of 10 μM metformin with 10 and 40 µM fluvastatin concentrations might be considered more significant in terms of providing precise and reliable measurements. Conclusion: The Significant change in this study in reductions of cytotoxic effects can be participated in the future as predictive marker for treatment.